PDCD1 and non-small cell lung carcinoma: For unselected NSCLC patients immunotherapy with immune checkpoint inhibitors (ICIs), including Anti-Programmed Cell Death Protein 1 (anti-PD-1) and Anti-Programmed Death-Ligand 1 (anti-PD-L1) is a promising treatment strategy [61].